Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyNeuro-OncologyradiotherapyThoracic TumorsTumor, regardless of entityDiseaseBreast CancerLung Carcinoma, Non-Small CellLung Carcinoma, Small CellMalignant MeningitisThyroid CancerTumor, Various OrgansTumor Biomarker DefinedSubgroupALK+BRAF V600E mutationEGFR activating mutationEGFR exon 19 deletion mutationEGFR exon 20 insertionEGFR exon 21 Leu858Arg mutationEGFR T790M mutationHER2+Her2-mutatedKRAS G12C-MutationMET AmplificationMETex14 skipping mutationnon-squamousPD-L1 >50%PD-L1 from 1%RET fusion positiveROS1+Squamous Cell CarcinomaStage IIIA/BICD10C34.-C50.-C73C79.3MeSHBreast NeoplasmsCarcinoma, Non-Small-Cell LungMeningeal CarcinomatosisNeoplasmsSmall Cell Lung CarcinomaThyroid NeoplasmsSequenceALTA-1L: BRGT(90/180), NSCLC, first line, C1 (PID48) -|- BRGT180, C2+ (PID49)ATEZ1200/BEVA15/PACL175/CRBP5, NSCLC (PID2525) -|- ATEZ1200/BEVA15, maint. (PID1209)AVAPERL: PEME500/CISP75/BEVA7.5, NSCLC, A (PID185) -|- BEVA 7.5 maint., B (PID187).AVAPERL: PEME500/CISP75/BEVA7.5, NSCLC, A (PID185) -|- PEME500/BEVA7.5 maint., B (PID186).BRGT(90/180), NSCLC, second line, C1 (PID54) -|- BRGT180, NSCLC, second line, C2+ (PID55)CALGB 9431: VINO25/CISP80, NSCLC, A (PID261) -|- VINO15/CISP80/Radiation, B (PID262).CETU(400/250)/CISP80/VINO25, NSCLC, C1 (PID190) -|- C2-6 (PID191) -|- Erh (PID192)CheckMate 9LA: NIVO360/IPIL1/PACL200/CRBP6, NSCLC (PID1670) -|- NIVO360/IPIL1, maint. (PID1671)CheckMate 9LA: NIVO360/IPIL1/PEME500/CISP75, NSCLC (PID1676) -|- NIVO360/IPIL1, maint. (PID1671)CheckMate 9LA: NIVO360/IPIL1/PEME500/CRBP6, NSCLC (PID1669) -|- NIVO360/IPIL1, maint. (PID1671)CHRYSALIS : AMIV(350/700/1050), NSCLC, C1 (PID1908) -|- AMIV1050, C2+ (PID1909)CHRYSALIS : AMIV(350/1050/1400), NSCLC, C1 (PID1912) -|- AMIV1400, C2+ (PID1913)CISP60/ETOP150, NSCLC, neoadj., C1-3 (PID620) -|- CISP50/ETOP100/Radiation, C1 (PID619).CM77T: NIVO360/CISP75/DOCE75, NSCLC, neoadj., C1-4 (PID2645) -|- NIVO480, adj., C5-18 (PID2646)CM77T: NIVO360/CRBP5/PACL175, NSCLC, neoadj., C1-4 (PID2642) -|- NIVO480, adj., C5-18 (PID2646)CM77T: NIVO360/CRBP5/PEME500, NSCLC, neoadj., C1-4 (PID2643) -|- NIVO480, adj., C5-18 (PID2646)CM77T: NIVO360/PEME500/CISP75, NSCLC, neoadj., C1-4 (PID2644) -|- NIVO480, adj., C5-18 (PID2646)DURV1500/GEMC1250/CISP75, NSCLC, neoadj., C1-4 (PID2493) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/GEMC1250/CRBP5, NSCLC, neoadj., C1-4 (PID2495) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/PACL200/CRBP6, NSCLC, neoadj., C1-4 (PID2496) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/PEME500/CISP75, NSCLC, neoadj., C1-4 (PID2492) -|- DURV1500, adj., C5-18 (PID2497)DURV1500/PEME500/CRBP5, NSCLC, neoadj., C1-4 (PID2494) -|- DURV1500, adj., C5-18 (PID2497)EMPOWER-Lung 3: CEMI350/PACL200/CISP75, NSCLC, C1-4 (PID2274) -|- CEMI350, C5+ (PID2276).EMPOWER-Lung 3: CEMI350/PACL200/CRBP6, NSCLC, C1-4 (PID2275) -|- CEMI350, C5+ (PID2276).EMPOWER-Lung 3: CEMI350/PEME500/CISP75, NSCLC, C1-4 (PID2273) -|- CEMI350/PEME500, C5+ (PID2272).EMPOWER-Lung 3: CEMI350/PEME500/CRBP6, NSCLC, C1-4 (PID2271) -|- CEMI350/PEME500, C5+ (PID2272).ESPATUE: PACL175/CISP50, NSCLC, ind., neoadj., A (PID 852) -|- VINO20/CISP50/Radiation B (PID 853) -|- possibly VINO15/CISP40/Radiation C (PID1169)FLAURA2: OSIM80/PEME500/CISP75, NSCLC, C1-4 (PID2540) -|- OSIM80/PEME500, C5+ (PID2541)FLAURA2: OSIM80/PEME500/CRBP5, NSCLC, C1-4 (PID2543) -|- OSIM80/PEME500, C5+ (PID2541)IMpower130: ATEZ1200/CRBP6/NPAC100, NSCLC (PID1238) -|- ATEZ1200/CRBP6/NPAC100 - ATEZ1200 maint. (PID1272)IMpower150: ATEZ1200/BEVA15/PACL200/CRBP6, NSCLC (PID1208) -|- ATEZ1200/BEVA15, maint. (PID1209)KEYNOTE-021: PEMB200/PEME500/CRBP5, NSCLC (PID842) -|- PEMB200, maint. (PID1083)KEYNOTE-189: PEMB200/PEME500/CISP75, NSCLC (PID1177) -|- PEMB200/PEME500, maint. (PID1170)KEYNOTE-189: PEMB200/PEME500/CRBP5, NSCLC (PID842) -|- PEMB200/PEME500, maint. (PID1170)KEYNOTE-407: PEMB200/NPAC100/CRBP6, NSCLC (PID35) -|- PEMB200, maint. (PID1083)KEYNOTE-407: PEMB200/PACL200/CRBP6, NSCLC (PID36) -|- PEMB200, maint. (PID1083)NADIM II: NIVO360/PACL200/CRBP5, NSCLC, neoadj., C1-3 (PID2387) -|- NIVO480, adj., C4-9 (PID2388)NIVO360/PACL200/CRBP6/BEVA15, NSCLC (PID1929) -|- NIVO360/BEVA15, maint. (PID2126)PACL45/CRBP2/Radiation, NSCLC A (PID253) -|- PACL200/CRBP6 cons., B (PID254)PACL50/CRBP2/Radiation, NSCLC A (PID255) -|- PACL200/CRBP6 cons., B (PID256)PACL200/CRBP6/BEVA15, NSCLC (Adeno) A (PID130) -|- BEVA15 maint., B (PID167)PARAMOUNT: PEME500/CISP75, NSCLC, A (PID179) -|- PEME500, B, maint. (PID180)PEMB200/CISP75/GEMC1000, NSCLC, neoadj., cycle 1-4 (PID2376) -|- PEMB200, adj., cycle 5-18 (PID2378)PEMB200/PEME500/CISP75, NSCLC, neoadj., cycle 1-4 (PID2377) -|- PEMB200, adj., cycle 5-18 (PID2378)PEME50/DEXA5, Malignant Meningitis, C1 (PID2529) -|- C2 (PID2530) -|- C3+ (PID2531)PEME500/CISP75/Radiation, NSCLC, A (PID247) -|- PEME500 cons., B (PID249).PEME500/CRBP5/AMIV(350/1050/1400), NSCLC, C1 (PID2498) -|- C2 (PID2499) -|- C3-4 (PID2500) -|- C5+ (PID2501)PEME500/CRBP5/Radiation, NSCLC (Adeno) A (PID250) -|- PEME500 cons., B (PID251)PEME500/CRBP6, NSCLC (Adeno) A (PID181) -|- PEME500 maint., B (PID182)PEME500/CRBP6/BEVA15, NSCLC (Adeno) A (PID183) -|- PEME500/BEVA15 maint., B (PID184)PEME500/CRBP6/BEVA15, NSCLC (Adeno) A (Stevenson) (PID188) -|- BEVA15 maint., B (PID189)PERT840/TRAS8/DOCE75, NSCLC, C1 (PID1975) -|- PERT420/TRAS6/DOCE75, NSCLC, C2+ (PID1976)POSEIDON: TREM75/DURV1500/GEMC1250/CISP75, NSCLC, C1-4 (PID2294) -|- C5 (PID2291) -|- C6 (PID2292) -|- C7+ (PID2291)POSEIDON: TREM75/DURV1500/GEMC1250/CRBP6, NSCLC, C1-4 (PID2293) -|- C5 (PID2291) -|- C6 (PID2292) -|- C7+ (PID2291)POSEIDON: TREM75/DURV1500/NPAC100/CRBP6, NSCLC, C1-4 (PID2290) -|- C5 (PID2291) -|- C6 (PID2292) -|- C7+ (PID2291)POSEIDON: TREM75/DURV1500/PEME500/CISP75, NSCLC, C1-4 (PID2296) -|- C5 (PID2297) -|- C6 (PID2298) -|- C7+ (PID2297)POSEIDON: TREM75/DURV1500/PEME500/CRBP6, NSCLC, C1-4 (PID2295) -|- C5 (PID2297) -|- C6 (PID2298) -|- C7+ (PID2297)RATIONALE 304: TISL200/PEME500/CISP75, NSCLC (PID2634) -|- TISL200/PEME500, maint. (PID2636)RATIONALE 304: TISL200/PEME500/CRBP5, NSCLC (PID2635) -|- TISL200/PEME500, maint. (PID2636)RATIONALE 307: TISL200/NPAC100/CRBP5, NSCLC (PID2648) -|- TISL200, maint. (PID2649)RATIONALE 307: TISL200/PACL175/CRBP5, NSCLC (PID2647) -|- TISL200, maint. (PID2649)ChemotherapyChemo-substanceAdagrasibAfatinibAlectinibAmivantamabAtezolizumabBevacizumabBleomycinBrigatinibCapmatinibCarboplatinCemiplimabCeritinibCetuximabCisplatinCrizotinibDabrafenibDacomitinibDexamethasoneDocetaxelDurvalumabEntrectinibErlotinibEtoposideGefitinibGemcitabineHydrocortisoneIfosfamideIpilimumabLorlatinibMitomycinNab-paclitaxelNintedanibNivolumabNivolumab-RelatlimabOsimertinibPaclitaxelPembrolizumabPemetrexedPertuzumabPralsetinibRamucirumabSelpercatinibSotorasibTepotinibThiotepaTislelizumabTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabVemurafenibVinblastineVinorelbineChemo-substanceAdagrasibAfatinibAlectinibAmivantamabAtezolizumabBevacizumabBleomycinBrigatinibCapmatinibCarboplatinCemiplimabCeritinibCetuximabCisplatinCrizotinibDabrafenibDacomitinibDexamethasoneDocetaxelDurvalumabEntrectinibErlotinibEtoposideGefitinibGemcitabineHydrocortisoneIfosfamideIpilimumabLorlatinibMitomycinNab-paclitaxelNintedanibNivolumabNivolumab-RelatlimabOsimertinibPaclitaxelPembrolizumabPemetrexedPertuzumabPralsetinibRamucirumabSelpercatinibSotorasibTepotinibThiotepaTislelizumabTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabVemurafenibVinblastineVinorelbineChemo-substanceAdagrasibAfatinibAlectinibAmivantamabAtezolizumabBevacizumabBleomycinBrigatinibCapmatinibCarboplatinCemiplimabCeritinibCetuximabCisplatinCrizotinibDabrafenibDacomitinibDexamethasoneDocetaxelDurvalumabEntrectinibErlotinibEtoposideGefitinibGemcitabineHydrocortisoneIfosfamideIpilimumabLorlatinibMitomycinNab-paclitaxelNintedanibNivolumabNivolumab-RelatlimabOsimertinibPaclitaxelPembrolizumabPemetrexedPertuzumabPralsetinibRamucirumabSelpercatinibSotorasibTepotinibThiotepaTislelizumabTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabVemurafenibVinblastineVinorelbineChemo-substanceAdagrasibAfatinibAlectinibAmivantamabAtezolizumabBevacizumabBleomycinBrigatinibCapmatinibCarboplatinCemiplimabCeritinibCetuximabCisplatinCrizotinibDabrafenibDacomitinibDexamethasoneDocetaxelDurvalumabEntrectinibErlotinibEtoposideGefitinibGemcitabineHydrocortisoneIfosfamideIpilimumabLorlatinibMitomycinNab-paclitaxelNintedanibNivolumabNivolumab-RelatlimabOsimertinibPaclitaxelPembrolizumabPemetrexedPertuzumabPralsetinibRamucirumabSelpercatinibSotorasibTepotinibThiotepaTislelizumabTrametinibTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTremelimumabVemurafenibVinblastineVinorelbineNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMesnaMinocyclineParacetamolPegfilgrastimPotassium chloridePrednisoloneNo. Substances12345678911Protocol classificationTherapy classificationalternativecurrent standardstudy analogIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseConsolidationInductionMaintenanceneoadjuvantTherapy intentioncurativepalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityColitisConjunctivitisConstipationDehydrationDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Endocrine Side EffectsEsophagitisExanthema, AcneiformFatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHemorrhageHepatotoxicityHyperbilirubinemiaHypercholesterolemiaHyperglycemiaHyperkalemiaHyperkeratosisHyperphosphatemiaHypertensionHyperthyroidismHypertriglyceridemiaHypoalbuminemiaHypocalcemiaHypokalemiaHyponatremiaHypophosphatemiaHypophysitisHypotensionHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesIncrease Creatinine PhosphokinaseInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisMyalgiasNail ChangesNasopharyngitisNauseaNephritisNeuropathyNeurotoxicityNeutropeniaOral MucositisPainParesthesiaPhotosensitivityPneumoniaPneumonitisProteinuriaPruritusPyrexiaQTc Time ExtensionRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVisual DisturbancesVomiting only studiesPublicationAuthorAlbain KSAntonia SArriagada RArriagada R Belani CPBerghmans TBrahmer JCamidge DCappuzzo FCascone TChandra P. BelaniCho BCChoy HC ManegoldC SederholmCurran WDouillard, JYDrilon AEberhardt WE F SmitE QuoixFan CF A ShepherdF BarlesiFelip EF FossellaForde PMGainor JFGandhi LGaron EGeorgoulias VG FrasciGogishvili MGoss GGridelli CGustave Roussy, Villejuif, FranceG V ScagliottiHeigener DFHelbekkmo NHellmann MDHerbst RHeymach JV Hirose TJ-L PujolJD HainsworthJD PatelJoan H. SchillerJohnson MLJP StevensonJänne PAKaira KKawaguchi TKim DKosmidis PKunitoh H Langer CL G Paz-AresLi BTLu SMaisch BMartinoni A Mazieres JM KarayamaMok TMok T SM ZukinNakagawa KN HannaO'Brien MPaik PKPark KPark SPaz-Ares LPeters SP FidiasPirker RP KosmidisPlanchard D Provencio MPujol JLReck MRittmeyerR M RuddRossel RSandler, A.Scagliotti et alSchiller JH et al.Schuler M Semrau SSequist LVSeto TSezer AShaw AShaw ATSkoulidis FSocincki MSocinski MSocinski MASolomon BSolomon BJSoria JSoria JCStrauss GMSugawara SVokes EEWakelee HWang JWest HWinton T WJ TesterWolf JW SchuetteW SchütteWu YLZhong WZZhou CDiseaseAdenokarzinom nichtkleinzelliges Lungenkarzinom, Stadium IIIb/IV oder rezidiviert, ECOG 0-1fortgeschrittenes (Stadium IIIb) oder metastasiertes NSCLC (Patienten älter als 70 Jahre)fortgeschrittenes, metastasiertes oder wiederkehrendes nichtkleinzelliges Adenokarzinom der Lunge, ECOG 0-1Fortgeschrittenes, nichtkleinzelliges Lungenkarzinom, Stadium IIIA und IIIB, Erstlinie, ECOG 0-1fortgeschrittenes, plattenepitheliales, nichtkleinzelliges Lungenkarzinom nach Platinhaltiger Therapie, ECOG 0-1fortgeschrittenes NSCLC, BRAF V600-Mutation, ECOG 0-2fortgeschrittenes NSCLC, nichtresezierbares, Stadium III, ECOG 0-1fortgeschrittenes oder metastasiertes NSCLC, ALK Translokation, Erstliniefortgeschrittenes oder metastasiertes NSCLC, ALK Translokation, Zweitlinie nach Crizotiniblokal fortgeschrittenes, nichtresektables, nichtkleinzelliges Lungenkarzinom, Stadium III, nach Platin und Radiotherapie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Lungenkarzinom, ALK+, Erstlinie, ECOG 0-2lokal fortgeschrittenes oder metastasiertes Lungenkarzinom, ALK+, Progress unter Crizotinib, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Lungenkarzinom, Erstlinie, EGFR Exon 20 Insertionen, ECOG 0-1Maligner Perikarderguss, hämodynamisch relevantMaligner Perikarderguss beim NSCLC, hämodynamisch relevantMeningeosis neoplastica bei NSCLC, EGFR+, nach Vortherapie mit TKI, ECOG 1-3metastasiertes Lungenkarzinom, Erstlinie, PD-L1 ab 1%, ECOG 0-1Metastasiertes oder fortgeschrittenes nichtkleinzelliges Lungenkarzinom, ECOG 0-1metastasiertes oder fortgeschrittenes nichtkleinzelliges Lungenkarzinom, ECOG 0-1Metastasiertes oder lokal fortgeschrittenes, nicht operables NSCLC, ALK+, Erstlinie, ECOG 0-2Nichtkleinzelliges Lungen-Ca Stadium IIIb, IV oder RezidivNichtkleinzelliges Lungen-Ca Std. IIIb, IV oder Rezidivnichtkleinzelliges Lungenkarzinom (Adenokarzinom), Stadium IB-IIIA, neoadjuvant, ECOG 0-1, ALK und EGFR neg.nichtkleinzelliges Lungenkarzinom (Plattenepithelkarzinom), Stadium IB-IIIA, neoadjuvant, ECOG 0-1, ALK und EGFR neg.nichtkleinzelliges Lungenkarzinom, Adeno-, Stadium IV, Erstlinie, ECOG 0-1nichtkleinzelliges Lungenkarzinom, Plattenepithel-, Stadium IV, Erstlinie, ECOG 0-1nichtkleinzelliges Lungenkarzinom, Stadium I, II und III, adjuvant, ECOG 0-1Nichtkleinzelliges Lungenkarzinom, Stadium IB, II, IIIA (UICC 8), ECOG 0-1nichtkleinzelliges Lungenkarzinom, Stadium IB-IIIA, neoadjuvant, ECOG 0-1, ALK und EGFR neg.nichtkleinzelliges Lungenkarzinom, Stadium IB-IIIA, R0-Resektion, adjuvant, ECOG 0-1Nichtkleinzelliges Lungenkarzinom, Stadium II, IIIA, or IIIB (N2), ECOG 0-1nichtkleinzelliges Lungenkarzinom, Stadium II, IIIA, or IIIB (N2), ECOG 0-1Nichtkleinzelliges Lungenkarzinom, Stadium II-IIIA, adjuvant, nach platinbasierter ChemotherapieNichtkleinzelliges Lungenkarzinom, Stadium IIA/IIIB, ECOG 0-1, ALK und EGFR neg.Nichtkleinzelliges Lungenkarzinom, Stadium IIIA/IIIB, ECOG 0-1, ALK und EGFR neg.Nichtkleinzelliges Lungenkarzinom lokal fortgeschritten oder metastasiert, ROS1+, ECOG 0-2nicht resezierbares NSCLC, Stadium I-IIIB, ECOG 0-3Nicht resezierbares NSCLC, Stadium IIIA und IIIB, Erstlinie, ECOG 0-2NSCLC (Adeno-), Stadium IIIb oder IV, EGFR- und ALK-, Erstlinie, ECOG 0-1NSCLC (Adeno-) Stadium III (maligner Pleuraerguss) und Stadium IV, ECOG PS 2NSCLC (Adeno-) Stadium IIIA und IIIB (ohne Pleuraerguss), ECOG 0-1NSCLC (Adeno-) Stadium IIIb (maligner Pleuraerguss) und Stadium IV, ECOG PS 2NSCLC (Adeno-) Stadium IIIb oder IVNSCLC(Adeno-) Std. IIIb und Std. IV, Wenig- oder NichtraucherNSCLC (Adeno-, EGFR-Mutation+) fortgeschrittenNSCLC (Adenokarzinom), Stadium IB-IIIA, EGFR mutiert (Ex19del oder L858R), adjuvant, ECOG 0-1NSCLC (Nicht-Plattenepithel) inoperabel Std. IIIb u Std. IVNSCLC (Nicht-Plattenepithel) Stadium IIIb (maligner Pleuraerguß) und Stadium IVNSCLC (Nicht-Plattenepithel) Stadium IIIb (mit Pleuraerguß) und Stadium IVNSCLC (Nicht-Plattenepithel) Stadium IIIb(spraclavic. Lymphknoten, malig. Pleura- oder Perikardergüsse) und Stadium IVNSCLC (Nicht-Plattenepithel) Std. IIIb (supraclavic. Lymphknoten, malig. Pleura- oder Perikardergüsse) und Std. IVNSCLC, ECOG 0-2, perioperativNSCLC, lokal fortgeschritten oder metastasiert, Her2+, nach vorheriger Therapie, ECOG 0-1NSCLC, metastasiert, ECOG 0-2, ErstlinieNSCLC, potenziell resezierbar, Stadium IIIA oder IIIB, ECOG 0-1NSCLC, Stadium IB, II oder IIIA, ALK+, ECOG 0-1NSCLC, Stadium III, nicht operabel, EGFR mutiert (Ex19del oder L858R), nach Radiochemotherapie, ECOG 0-1NSCLC, Stadium IIIa und IIIb, ECOG 0-1, therapie-naivNSCLC, Stadium IIIa und Stadium IIIb, ECOG 0-1, therapie-naivNSCLC, Stadium IIIB oder IV, ALK+, Erstlinie, ECOG 0-2NSCLC, Stadium IIIB oder IV, ALK+, Zweitlinie nach Crizotinib, ECOG 0-2NSCLC, Stadium IIIB oder IV, ECOG 0-1NSCLC, Stadium IIIB oder IV, ELK/EGFR neg., ECOG 0-1NSCLC, Stadium IIIb und IV, Patienten über 70 JahreNSCLC, Stadium II und III, nicht resezierbar, Karnofsky > 70NSCLC, Stadium IV, BRAF V600 mutiert, Erstlinie, ECOG 0-2NSCLC, STD. IIIb (mit Pleuraerguss) und Std. IV, älter als 70 Jahre, chemo-naiv, ECOG 0-1NSCLC, Zweitlinie nach Platinkombination oder TKI, PD-L1 Expression > 1%, ECOG 0-1NSCLC fortgeschritten oder metastasiert, ALK+, Erstlinie, ECOG 0-2NSCLC fortgeschritten oder metastasiert, ALK+, ZweitlinieNSCLC fortgeschritten oder metastasiert, Erstlinie, WHO 0-2NSCLC fortgeschritten oder metastasiert, METex14+, ECOG 0-2NSCLC fortgeschritten oder metastasiert, nach VortherapieNSCLC fortgeschritten oder metastasiert, Progress nach platinbasierter Therapie, ECOG 0-1NSCLC fortgeschritten oder metastasiert, ROS1+, ECOG 0-2NSCLC fortgeschritten oder metastasiert, Zweitlinie nach Progress unter TKI, WHO 0-2NSCLC fortgeschritten und metastasiert, Progress unter mind. einer platinbasierten VortherapieNSCLC fortgeschritten und metastasiert, Progress unter mind. einer platinbasierten Vortherapie, ECOG 0-2NSCLC im Stadium IIIB/IV, EGFR Mutation, keine Vortherapie für die fortgeschrittene Erkrankung, keine Hirnmetastasen, ECOG 0-1NSCLC im Stadium IIIB oder IV, MET Exon 14 Mutation oder MET Amplifikation, ECOG 0-1NSCLC im Stadium IIIB oder IV, MET Exon 14 Skipping Mutation, nach vorherigen Therapie, ECOG 0-1NSCLC im Stadium IV, EGFR mutiert (Exon 19 Deletion oder Exon 21 Substitution), ECOG 0-1, keine zerebralen MetastasenNSCLC inoperabel (Stadium IIIa und b), Rezidiv oder Metastasen, Stadium IVNSCLC inoperabel (Std. IIIa u b), Rezidiv oder Metastasen, Std. IVNSCLC lokal fortgeschritten, inoperabel, oder metastasiert, Her2-Mutation, Progress nach platinhaltiger TherapieNSCLC lokal fortgeschritten, nicht operabel oder metastasiert, PD-L1 Expression über 50%, ECOG 0-1NSCLC lokal fortgeschritten, oder metastasiert, EGFR Exon-19-Deletion oder L858R-Mutation, ECOG 0-1NSCLC lokal fortgeschritten oder metastasiert, taxanhaltige Vortherapie, Karnofsky Index 50-100NSCLC metastasiert, nach Rezidiv oder Nichtansprechen einer Vortherapie, ECOG 0-1, ZweitlinieNSCLC metastasiert oder lokal fortgeschritten, RET-Fusion, ECOG 0-2NSCLC metastasiert oder lokal fortgeschritten mit KRAS p.G12C Mutation, Progress nach Immuntherapie und/oder platinbasierter Chemotherapie, ECOG 0-1NSCLC nicht resezierbar oder metastasiert, nach 4 Zyklen platinbasierter Kombinationstherapie ohne ProgressNSCLC nicht resezierbar Stadium IIIb (mit oder ohne Pleuraerguss) und Stadium IVNSCLC Stad. IIIb od IV ohne Eignung für OP oder kurative Radiatio (außer bronchoalveoläres Ca)NSCLC Stadium III (nicht für Radiatio geeignet) und Stadium IV , Patienten älter als 70 JahreNSCLC Stadium IIIa und Stadium IIIbNSCLC Stadium IIIbNSCLC Stadium IIIb (Pleuraerguss oder met. supraclavic. Lymphknoten) und Stadium IV, Patienten älter als 70 JahreNSCLC Stadium IIIb, IV oder RezidivNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic.Lymphknoten und Stadium IVNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic. Lymphknoten und Stadium IV, < 70 JahreNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic.Lymphknoten und Stadium IV, jünger als 70 JahreNSCLC Stadium IIIb mit malig. Pleuraergüssen oder supraclavic. Lymphknoten und Stadium IV, jünger als 70 JahreNSCLC Stadium IIIb mit malignen Pleuraergüssen oder supraclavic. Lymphknoten und Stadium IVNSCLC Stadium IIIb oder IV, (Plattenepithel-), Zweitlinie nach platinbasierter Therapie, ECOG 0-1NSCLC Stadium IIIb oder IV, Erstlinie für fortgeschrittene Erkrankung, ECOG 0-1NSCLC Stadium IIIB oder IV, Zweit- oder Drittlinie nach Platin, ECOG 0-1NSCLC Stadium IIIb oder IV ohne Eignung für OP oder kurative Radiatio (außer bronchoalveoläres Ca)NSCLC Stadium IIIb und IVNSCLC Stadium IIIb und IV, exclusive vorrangiger histolog. PlattenepithelkomponenteNSCLC Stadium IIIb und IV, palliativNSCLC Stadium IIIb und IV ohne Eignung zur kurativen TherapieNSCLC Stadium IIIb und Stadium IVNSCLC Stadium IIIb und Stadium IV, EGFR-ExpressionNSCLC Stadium III nicht resezierbarNSCLC Stadium III und IV, palliativ, ZweitlinieNSCLC Stadium IV, PD-L1 Expression > 50%, keine EGFR Mutationen / ALK Translokationen, Erstlinie, ECOG 0-1NSCLC Stadium IV mit Progress unter oder nach Platinum-basierter ErstlinieNSCLC Stadium T2N0, T1N1, T2N1 in adjuvantem Setting nach KomplettresektionNSCLC Stadium V oder IIIb ohne Eignung für multimod. Therapie, Patienten älter als 65 und nicht für Kombinationschemotherapie geeignet)NSCLC Std. I (nur T2N0), Std. II u Std. IIIa nach Komplettresektion, ECOG 0-2, exclusive histolog. brochoalveoläres Ca.NSCLC Std. I, II u III nach KomplettresektionNSCLC Std. IIIa (falls inoperabel), IIIb oder IVNSCLC Std. IIIb (mit Pleuraerguss) u Std. IV, EGFR Mut+(Deletion Exon 19 oder L858R Mut in Exon 21)NSCLC Std. IIIB oder IV, ECOG 0-2, jünger als 75 Jahre, ErstlinieNSCLC Std. IIIb u IV, palliativNSCLC Std. IIIb und IV NSCLC Std. IIIb und IV, Zweit- und Drittlinie bei Patienten ohne Eignung zur weiteren ChemotherapieNSCLC Std. IIIb und Std. IV, EGFR-ExpressionNSCLC Std. IVprogredientes NSCLC, ALK+, ECOG 0-2RET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Stadium IV oder rezidivierend metastasierendes NSCLC, Adeno-, ECOG 0-1 Stadium IV oder rezidivierend metastasierendes NSCLC, EGFR-Mutation oder ALK-Translokation, Progress unter TKIStd. Ib (T2 N0 M0) nach Resektion (Lobektomie oder Pneumektomie); ECOG 0-1vollständig reseziertes, EGFR+ nichtkleinzelliges Lungenkarzinom, Stadium II-IIIA, ECOG 0-1OriginAbramson Cancer Center of the University of Pennsylvania, KEYNOTE-021Abteilung für thorakale Onkologie, Krankenhaus Grosshansdorf, Universität Hamburg, DeutschlandAdjuvant Navelbine International Trialist Association (ANITA)American Society of Clinical OncologyBelani CP, University of Pittsburgh Cancer Institute, USABloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, CheckMate 816 trialCancer and Leukemia Group B, Radiation Therapie Group and North Central Cancer Treatment Study GroupsCancer and Leukemia Group B Studie 9431Cancer Center and Research Institute, Magnolia, Tampa, PACIFIC StudieCardiology Unit, Milan, ItalyChinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, RATIONALE 307 trialChoy H, University of Texas Southwestern, Dallas, TexasChoy H, Vanderbilt University Medical School, Nashville, USACHU Toulouse-Hopital Larrey, Universite Paul Sabatier, Toulouse, France, IFCT-1703 R2D2 TrialC Manegold, Thoraxklinik Heidelberg, DeutschlandDana-Farber Cancer Institute, Boston, USADepartment of Internal Medicine, Seoul National University Hospital, KoreaDepartment of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyDepartment of Internal Medicine and Radiotherapy, West German Cancer Center University, EssenDepartment of Medical Oncology, Baskent University, Adana, Turkey, EMPOWER-Lung 1Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, KEYNOTE-407Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, KEYNOTE-407 InvestigatorsDepartment of Medical Oncology, West German Cancer Centre, Ruhrlandklinik, ESPATUEDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, JapanDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, RTOG 9410Department of Radiotherapy, University of Rostock, Germany, PET-PlanDepartment of Thoracic Oncology, German Center for Lung Research, Germany, IMpower150 Study GroupDepartment of Thoracic Oncology, Grosshnasdorf, Germany, AVAiL trialEastern Cooperative Oncology GroupF A Shepherd, Department of Medical Oncology and Hematology and Radiation Ocology, Toronto, KanadaF Barlesi, Sce Oncologie Multidisciplinaire et Innovations Therapeutiques, Marseille, Frankreich. AVAPERL (MO22089)FLEX Studien TeamGerman Center for Lung Research, LungClinic, Grosshansdorf, Germany, CheckMate 9LAGuangdong Academy of Medical Sciences and General Hospital, China, ADAURA trialGuangdong Lung Cancer Institute, Guangdong General Hospital and Academy of Medical Sciences, Guangzhou, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, ALINA trialGustave Roussy Cancer Campus and Universitiy Paris-Sud, Orsay, FranceHanna N, Indiana University and Hoosier Oncology GroupHelbekkmo N, University of Tromso and Department of Oncology, NorwegenHigh Technology Medical Centre, University Clinic Ltd., Tbilisi, Georgia, EMPOWER-Lung 3Hospital Universitario 12 de Octubre, Universidad Complutense and CiberOnc, Madrid, Spain, CheckMate 9LA studyHospital Universitario Puerta de Hierro-Majadahonda, Spain, NADIM II trialInstitut Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Villejuif, France, FLAURA2 trialInstitut Jules Bordet, Universite Libre de Bruxelles, BelgiumIntergroupe Francophone de Cancerologie Thoracique, Institut National du Cancer, FrankreichIPASS StudieJ-L Pujol, Montpellier University Hospital, FrankreichJD Patel, R H Lurie Comprehensive Cancer Center, Chicago, USA. PointBreak-StudieJP Stevenson, Abramson Cancer Center, Philadelphia, USAKindai University Faculty of Medicine, Osaka, Japan, RELAYLausanne University Hospital, Lausanne, F. Hoffmann–La Roche, Basel, Switzerland, ALEX TrialLilienbaum R C, Yale Cancer Center, New Haven, USALondon Lung Cancer GroupLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, BostonLUME-Lung 1 Studien Gruppe, LUME-Lung 1 StudieLung Cancer Group - EORTC 08975Lung Clinic, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany, KEYNOTE-024Lungenfachklinik Immenhausen, Immenhausen, Germany, OAK trialLung Unit, Royal Marsden Hospital, London, UK, PEARLS/KEYNOTE-091LUX Lung 3 StudieLUX Lung 8 StudieMaebashi Red Cross Hospital, Department of Respiratory Medicine, Asahicho, Maebashi, JapanMassachusetts General Hospital, Boston, MAMassachusetts General Hospital, Boston, USA, ARROW trialMassachusetts General Hospital, Div. of Hematology -Oncology, USAMassachusetts General Hospital Cancer Center, Boston, USA, CROWN trialMemorial SloanKettering Cancer Center, New YorkMemorial Sloan Kettering Cancer Center, New YorkMemorial Sloan Kettering Cancer Center, New York, VISION trialMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, DESTINY-Lung01 trialMILES (The Multicenter Italian Lung Cancer in the Elderly Study)Minnie Pearl Cancer Research NetworkM Karamaya, Department of Internal Medicine, Hamamatsu University, JapanNational Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan, JCOG9811National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States IntergroupNational Hospital Organization, Kinki-Chuo Chest Medical Center, JapanNational Kyushu Cancer Center, Fukuoka, JapanNew York University Langone Health, Laura and Isaac Perlmutter Cancer Center, New York, KEYNOTE-189 InvestigatorsPaz-Ares, Servicio de Oncologia Medica, Seville, Spanien, PARAMOUNT-StudiePaz-Ares, Servicio de Oncologia Medica, Seville, Spanien; PARAMOUNT-StudiePeter MacCallum Cancer Centre, Melbourne, VIC, AustraliaPeter MacCallum Cancer Centre, Melbourne, Victoria, AustralienPirker R, FLEX Studien TeamP Kosmidis, Second Medical Oncology Department, Hygeia Hospital, Athen, GriechenlandPlanchard DSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, ATTLAS trialSarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, POSEIDON StudySATURN investigators, SATURN StudieScagliotti, Department of Clinical and Biological Sciences, Turin, ItalienScagliotti, Dept. of Clinical and Biological sciences, University of Torino, ItalySecond Medical Oncology Department, Hygeia Hospital, Athen, GriechenlandShanghai Chest Hospital, Department of Oncology, Shanghai, People's Republic of China, RATIONALE 304 trialShanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, LAURA trialShanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, PAPILLON trialSidney Kimmel Comprehensive Cancer Center, Baltimore, USA, CheckMate 017Socinski MA, University of Pittsburgh Medical Center, Pittsburgh, USASouthern Italy Cooperative Oncology Group and Interr. Assc. for the Study of Lung Carcinoma, ItalienSouthwest Oncology Group, SWOG 9019Spanish Cancer Group, Groupe Francais de Pneumo-Cancerologie and Assz. Ital. Oncologia Toracica; EURTAC StudieStanford University School of Medicine, Stanford Cancer Institute, Stanford, CA, KEYNOTE-671State Key Laboratory of South China, Chinese University of Hong Kong, ARCHER 1050-StudieSungkyunkwan University School of Medicine,Seoul, South Korea, CHRYSALIS trialTAX 320 Non-Small-Cell Lung Cancer Study Group, USAThe First Department of Internal Medicine, Showa University School of Medicine, Tokyo, JapanThe Greek Oncology Cooperative Group for Lung CancerThe International Adjuvant Lung Cancer Trial Collaborative GroupThe Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials GroupThe Ottawa Hospital Cancer Centre, University of Ottawa, Canada, AURA2The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of ChinaThe Swedish Lung Cancer Study GroupThe TAX 326 Study Groupthe TAX 326 Study GroupThoracic Oncology Program, Swedish Cancer Institute, Seattle, USA, IMpower130Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, CheckMate 227 TrialThoracic Oncology Unit, IFCT, Respiratory Disease Department, Larrey Hospital, CHU, Toulouse, AcSé trialTongji University School of Medicine, Shanghai, People's Republic of China, RATIONALE 304Translational Research in Oncology-US Network, Los Angeles, USA ; REVEL StudieUniversity Hospital Cologne, Cologne, Germany, GEOMETRY mono-1 trialUniversity Hospital Essen, Essen, Germany, NEOAD trialUniversity of Colorado Cancer Center, Anschutz Cancer Pavilion, ALTA-1LUniversity of Texas, M.D. Anderson Cancer Center, Houston, USA, CodeBreaK100 trialUniversity of Texas M.D. Anderson Cancer Center, Houston, AEGEAN trialUniversity of Texas M.D. Anderson Cancer Center, Houston, CheckMate 77TUniversity Paris-Sud, Orsay, FranceVall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain, IMpower010Vanderbilt University, Nashville, Eastern Cooperative Oncology Group (ECOG), USAWeill Cornell Medical College, New York, USAWJ Tester, Alber Einstein Cancer Center, Philadelphia, USAW Schuette, Martha-Maria Stadtkrankenhaus Halle-Doelau, DeutschlandW Schütte, Städtisches Krankenhaus Martha-Maria Halle-Dölau, Universität Halle-WittenbergYale School of Medicine, New Haven, CT Weill Cornell Medical Center, New YorkYale School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, KEYNOTE-010Yonsei Cancer Center, Yonsei University College of Medicine, SeoulProtocols in Revision 222 protocols foundProtocols under revision.Adagrasib 600, Non-Small Cell Lung Cancer (PID2547)Afatinib 40, Non-Small Cell Lung Cancer (Squamous) (PID735)Afatinib 40, Non-Small Cell Lung Carcinoma, Adeno- (PID197)Alectinib 600, Non-Small Cell Lung Cancer (ALK+), First-Line (PID975)Alectinib 600, Non-Small Cell Lung Cancer (ALK+), Second Line (PID888)Alectinib 600, Non-Small Cell Lung Cancer, adjuvant (PID2614)Amivantamab (350/1050/1400), Non-Small Cell Lung Cancer, cycle 1 (PID1912)Amivantamab (350/700/1050), Non-Small Cell Lung Cancer, Cycle 1 (PID1908)Amivantamab 1050, Non-Small Cell Lung Cancer, cycle 2+ (PID1909)Amivantamab 1400, Non-Small Cell Lung Cancer, cycle 2+ (PID1913)Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2525)Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1208)Atezolizumab 1200 / Bevazicumab 15, Maintenance, Non-Small Cell Lung Cancer (PID1209)Atezolizumab 1200 / Carboplatin 6 / Nab-Paclitaxel 100 - Atezolizumab 1200 Maintenance, Non-Small Cell Lung Carcinoma (PID1272)Atezolizumab 1200 / Carboplatin 6 / Nab-Paclitaxel 100, Non-Small Cell Lung Cancer (PID1238)Atezolizumab 1200, Non-Small Cell Lung Cancer, adjuvant (PID2252)Atezolizumab 1200, Non-Small Cell Lung Cancer, First-Line (PID1690)Atezolizumab 1200, Non-Small Cell Lung Cancer, Second Line (PID886)Atezolizumab 1680, Non-Small Cell Lung Cancer, Second Line (PID1663)Atezolizumab 840, Non-Small Cell Lung Cancer, Second Line (PID1662)Bleomycin 15, Non-Small Cell Lung Cancer (PID2375)Brigatinib 180, Non-Small Cell Lung Cancer, First-Line, Cycle 2+ (PID49)Brigatinib 180, Non-Small Cell Lung Cancer, Second Line, Cycle 2+ (PID55)Brigatinib 90/180, Non-Small Cell Lung Cancer, First-Line, Cycle 1 (PID48)Brigatinib 90/180, Non-Small Cell Lung Cancer, Second Line, Cycle 1 (PID54)Capmatinib 400, Non-Small Cell Lung Cancer (PID1793)Carboplatin 5 / Vinorelbine 25, Non-Small Cell Lung Carcinoma (PID284)Cemiplimab 350 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2275)Cemiplimab 350 / Paclitaxel 200 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2274)Cemiplimab 350 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2271)Cemiplimab 350 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2273)Cemiplimab 350 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5+ (PID2272)Cemiplimab 350, Non-Small Cell Lung Carcinoma (PID1744)Cemiplimab 350, Non-Small Cell Lung Cancer, Cycle 5+ (PID2276)Ceritinib 450, Non-Small Cell Lung Cancer, First Line (PID1152)Ceritinib 450, Non-Small Cell Lung Cancer, Second Line (PID811)Cetuximab (400/250) / Cisplatin 80 / Vinorelbine 25, Non-Small Cell Lung Cancer, Cycle 1 (PID190)Cetuximab 250 / Cisplatin 80 / Vinorelbine 25 - Cetuximab 250 Maintenance, Non-Small Cell Lung Cancer (PID192)Cetuximab 250 / Cisplatin 80 / Vinorelbine 25, Non-Small Cell Lung Cancer, Cycle 2-6 (PID191)Cisplatin 100 / Etoposide 100, Non-Small Cell Lung Cancer, Adjuvant (PID243)Cisplatin 100 / Vinblastine 5 / Radiation, Non-Small Cell Lung Cancer (PID857)Cisplatin 20 / Vinorelbine 12.5 / Radiation, Non-Small Cell Lung Cancer (PID669)Cisplatin 30, Tumor, Various Organs (PID2371)Cisplatin 50 / Etoposide 100 / Radiation, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 4 (PID619)Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer (PID252)Cisplatin 50 / Etoposide 50 / Radiation, Non-Small Cell Lung Cancer, Variant 1 (PID858)Cisplatin 60 / Etoposide 150, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 1-3 (PID620)Cisplatin 80 / Gemcitabine 1250 / Bevacizumab 7.5, Non-Small Cell Lung Cancer (PID770)Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), First Line (PID807)Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), Second Line (PID198)Crizotinib 250, Non-Small Cell Lung Cancer (METex14+) (PID1984)Crizotinib 250, Non-Small Cell Lung Cancer (ROS1+) (PID806)Dabrafenib 150 / Trametinib 2, non-small cell lung cancer (PID578)Dacomitinib 45, Non-Small Cell Lung Cancer (PID1425)Docetaxel 35 weekly, Non-Small Cell Lung Cancer (PID166)Docetaxel 36 weekly, Non-Small Cell Lung Cancer (PID168)Docetaxel 75 / Carboplatin 6, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID154)Docetaxel 75 / Cisplatin 75, Non-Small Cell Lung Carcinoma (PID144)Docetaxel 75 / Nintedanib 200, Non-Small Cell (Adeno) Lung Carcinoma (PID433)Docetaxel 75, Non-Small Cell Lung Carcinoma (PID162)Docetaxel 85 / Gemcitabine 1000, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID156)Durvalumab 10, Non-Small Cell Lung Carcinoma (PID470)Durvalumab 1500 / Gemcitabine 1250 / Carboplatin 5, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2495)Durvalumab 1500 / Gemcitabine 1250 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2493)Durvalumab 1500 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2496)Durvalumab 1500 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2494)Durvalumab 1500 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2492)Durvalumab 1500 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5,7+ (PID2297)Durvalumab 1500, Non-Small Cell Lung Cancer (PID1715)Durvalumab 1500, Non-Small Cell Lung Cancer, adjuvant, cycle 5-17 (PID2497)Durvalumab 1500, Non-Small Cell Lung Cancer, Cycle 5,7+ (PID2291)Entrectinib 600, Non-Small Cell Lung Cancer (PID1745)Erlotinib 150 / Bevacizumab 15, Non-Small Cell (Adeno) Lung Carcinoma (PID742)Erlotinib 150 Maintenance, Non-Small Cell Lung Cancer (PID212)Erlotinib 150, Non-Small Cell Lung Cancer (second- and third-line) (PID195)Erlotinib 150, Non-Small Cell Lung Cancer, First Line (PID206)Gefitinib 250, non-small cell lung carcinoma (PID196)Gefitinib 250, Non-Small Cell Lung Cancer, Adjuvant (PID1162)Gemcitabine 1000 / Carboplatin 5, Non-Small Cell Lung Cancer (PID132)Gemcitabine 1000 / Cisplatin 100, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID146)Gemcitabine 1000, Non-Small Cell Lung Cancer (PID172)Gemcitabine 1100 / Docetaxel 100, Non-Small Cell Lung Cancer (PID526)Gemcitabine 1150, Non-Small Cell Lung Cancer (PID173)Gemcitabine 1200 / Carboplatin 5, Non-Small Cell Lung Cancer (PID160)Gemcitabine 1200 / Cisplatin 80, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID151)Gemcitabine 1200, Non-Small Cell Lung Cancer (PID174)Gemcitabine 1250 / Carboplatin 5, Non-Small Cell Lung Carcinoma (PID155)Gemcitabine 1250 / Cisplatin 80, Non-Small Cell Lung Carcinoma, Non-Small Cell (PID159)Gemcitabine 1250, Non-Small Cell Lung Cancer (PID171)Ifosfamide 2, Non-Small Cell Lung Carcinoma (PID1495)Lorlatinib 100, Non-Small Cell Lung Cancer (PID1344)Lorlatinib 100, Non-Small Cell Lung Cancer, First Line (PID1673)Mitomycin 2, Non-Small Cell Lung Cancer (PID2373)Mitomycin 8 / Vinorelbine 25, Non-Small Cell Lung Cancer (PID757)Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID213)Nivolumab - Relatlimab 320, Non-Small Cell Lung Cancer (PID2612)Nivolumab 240, Non-Small Cell Lung Cancer, Second Line (PID598)Nivolumab 3 / Ipilimumab 1, Non-Small Cell Lung Cancer (PID1231)Nivolumab 360 / Carboplatin 5 / Paclitaxel 175, Non-Small Cell Lung Cancer, neoadjuvant, cycle 1-4 (PID2642)Nivolumab 360 / Carboplatin 5 / Pemetrexed 500, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2643)Nivolumab 360 / Cisplatin 75 / Doxetaxel 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2645)Nivolumab 360 / Gemcitabine 1250 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant (PID2091)Nivolumab 360 / Ipilimumab 1 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1670)Nivolumab 360 / Ipilimumab 1 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer (PID1669)Nivolumab 360 / Ipilimumab 1 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID1676)Nivolumab 360 / Ipilimumab 1, Non-Small Cell Lung Cancer, Maintenance (PID1671)Nivolumab 360 / Paclitaxel 200 / Carboplatin 5, Non-Small Cell Lung Cancer, Neoadjuvant, Cycles 1-3 (PID2387)Nivolumab 360 / paclitaxel 200 / carboplatin 6 / bevacizumab 15 - Nivolumab 360 / bevacizumab 15, non-small cell lung cancer, maintenance (PID2126)Nivolumab 360 / Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15, Non-Small Cell Lung Cancer (PID1929)Nivolumab 360 / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, neoadjuvant (PID2096)Nivolumab 360 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant (PID2095)Nivolumab 360 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, neoadjuvant, Cycle 1-4 (PID2644)Nivolumab 480, Non-Small Cell Lung Cancer, adjuvant, Cycle 4-9 (PID2388)Nivolumab 480, Non-Small Cell Lung Cancer, adjuvant, Cycle 5-18 (PID2646)Osimertinib 80 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2543)Osimertinib 80 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2540)Osimertinib 80 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 5+ (PID2541)Osimertinib 80, Non-Small Cell Lung Cancer, Adjuvant (PID1672)Osimertinib 80, Non-Small Cell Lung Cancer, Maintenance (PID2697)Osimertinib 80, Non-Small Cell Lung Cancer, First Line (PID1100)Osimertinib 80, Non-Small Cell Lung Cancer, Second Line (PID812)Paclitaxel 100 / Carboplatin 2, Non-Small Cell Lung Cancer (PID205)Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID148)Paclitaxel 175 / Cisplatin 50, Non-Small Cell Lung Cancer, Induction, Neoadjuvant, Part A (PID852)Paclitaxel 175 / Cisplatin 80, Non-Small Cell Lung Cancer (PID157)Paclitaxel 175 / Gemcitabine 1250, Non-Small Cell Lung Cancer (PID158)Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance , Non-Small Cell Lung Cancer, (Adeno) Part A (PID130)Paclitaxel 200 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID167)Paclitaxel 200 / Carboplatin 6 consolidation after Paclitaxel 45 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer Part B (PID254)Paclitaxel 200 / Carboplatin 6 consolidation after Paclitaxel 50 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer Part B (PID256)Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID170)Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer, adjuvant (PID246)Paclitaxel 200 / Gemcitabine 1000, Non-Small Cell Lung Cancer (PID169)Paclitaxel 200, Non-Small Cell Lung Cancer (PID193)Paclitaxel 225 / Carboplatin 6, Non-Small Cell Lung Cancer (PID92)Paclitaxel 45 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer, Part A (PID253)Paclitaxel 50 / Carboplatin 2 / Radiation, Non-Small Cell Lung Cancer, Part A (PID255)Paclitaxel 90, Non-Small Cell Lung Cancer (PID194)Pembrolizumab / Paclitaxel 200 / Carboplatin 6, Non-Small Cell Lung Cancer (PID36)Pembrolizumab 200 / Cisplatin 75 / Gemcitabine 1000, Non-Small Cell Lung Cancer, Neoadjuvant, Cycle 1-4 (PID2376)Pembrolizumab 200 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer (PID35)Pembrolizumab 200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer (PID842)Pembrolizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID1177)Pembrolizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Neoadjuvant, Cycles 1-4 (PID2377)Pembrolizumab 200 / Pemetrexed 500, Non-Small Cell Lung Cancer, Maintenance (PID1170)Pembrolizumab 200, non-small cell lung cancer, adjuvant (PID2170)Pembrolizumab 200, Non-Small Cell Lung Cancer, adjuvant, Cycle 5-18 (PID2378)Pembrolizumab 200, Non-Small Cell Lung Cancer, Maintenance (PID1083)Pembrolizumab 200, Non-Small Cell Lung Cancer, First-Line (PID809)Pembrolizumab 200, Non-Small Cell Lung Cancer, Second Line (PID808)Pembrolizumab 400, Non-Small Cell Lung Cancer, First Line (PID1252)Pembrolizumab 400, Non-Small Cell Lung Cancer, Second Line (PID1253)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 1 (PID2529)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 2 (PID2530)Pemetrexed 50 / Dexamethasone 5, intrathecal, Malignant Meningitis, cycle 3+ (PID2531)Pemetrexed 500 / Amivantamab 1750, Non-Small Cell Lung Cancer, Cycle 5+ (PID2501)Pemetrexed 500 / Carboplatin 5 / Amivantamab (350/1050/1400), Non-Small Cell Lung Cancer, Cycle 1 (PID2498)Pemetrexed 500 / Carboplatin 5 / Amivantamab 1400, Non-Small Cell Lung Cancer, Cycle 2 (PID2499)Pemetrexed 500 / Carboplatin 5 / Amivantamab 1750, Non-Small Cell Lung Cancer, Cycle 3-4 (PID2500)Pemetrexed 500 / Carboplatin 5 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell Lung Cancer, (Adeno) Part A (PID250)Pemetrexed 500 / Carboplatin 5 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell Lung Cancer (Adeno) Part B (PID251)Pemetrexed 500 / Carboplatin 5, non-small cell lung carcinoma (Adeno-) (PID178)Pemetrexed 500 / Carboplatin 6 - Pemetrexed 500 Maintenance, Non-Small Cell (Adeno) Lung Cancer, Part A (PID181)Pemetrexed 500 / Carboplatin 6 - Pemetrexed 500 Maintenance, Non-Small Cell (Adeno) Lung Cancer, Part B (PID182)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance, Non-Small Cell Lung Carcinoma, Non-Small Cell (Adeno) Part A (Stevenson) (PID188)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Bevacizumab 15 Maintenance, Non-Small Cell Lung Carcinoma, Non-Small Cell (Adeno) Part B (Stevenson) (PID189)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Pemetrexed 500 / Bevacizumab 15 maintenance, non-small cell lung carcinoma (Adeno-) part A (PID183)Pemetrexed 500 / Carboplatin 6 / Bevacizumab 15 - Pemetrexed 500 / Bevacizumab 15 maintenance, non-small cell lung cancer (Adeno) Part B (PID184)Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer (PID177)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 7.5 - Bevacizumab 7.5 Maintenance, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID187)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 7.5 - Pemetrexed 500 / Bevacizumab 7.5 Maintenance, Non-Small Cell Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID186)Pemetrexed 500 / Cisplatin 75 / Bevacizumab 7.5, Non-Small Cell Lung Cancer, Part A (PID185)Pemetrexed 500 / Cisplatin 75 / Radiation - Pemetrexed 500 Consolidation, Non-Small Cell (Adeno) Lung Carcinoma, Non-Small Cell (Adeno) Part B (PID249)Pemetrexed 500 / Cisplatin 75 / Radiation, Non-Small Cell Lung Cancer, Part A (PID247)Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID27)Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Part A (PID179)Pemetrexed 500, Non-Small Cell Lung Cancer, Non-Small Cell (Adeno), First-Line (PID176)Pemetrexed 500, Non-Small Cell Lung Cancer, Non-Small Cell (Adeno), Second Line (PID175)Pemetrexed 500, Non-Small Cell Lung Cancer, Part B, Maintenance (PID180)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Non-Small Cell Lung Cancer, Cycle 2+ (PID1976)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Non-Small Cell Lung Cancer, Cycle 1 (PID1975)Pralsetinib 400, Non-Small Cell Lung Cancer (PID1936)Ramucirumab 10 / Docetaxel 75, Non-Small Cell Lung Cancer (PID223)Ramucirumab 10 / Erlotinib 150, Non-Small Cell Lung Cancer (PID1487)Selpercatinib 160, Tumor Biomarker Defined (PID1732)Sotorasib 960, Non-Small Cell Lung Cancer (PID1914)Tepotinib 450, Non-Small Cell Lung Cancer (PID1983)Thiotepa 15 / Hydrocortisone 30, Tumor, Various Organs (PID2372)Tislelizumab 200 / Nab-Paclitaxel 100 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2648)Tislelizumab 200 / Paclitaxel 175 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2647)Tislelizumab 200 / Pemetrexed 500 / Carboplatin 5, Non-Small Cell Lung Cancer (PID2635)Tislelizumab 200 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer (PID2634)Tislelizumab 200 / Pemetrexed 500, Non-Small Cell Lung Cancer, Maintenance (PID2636)Tislelizumab 200, Non-Small Cell Lung Cancer (PID2650)Tislelizumab 200, Non-Small Cell Lung Cancer, Maintenance (PID2649)Trastuzumab Deruxtecan 5.4, Non-Small Cell Lung Cancer (PID1977)Trastuzumab Emtansine 3.6, Non-Small Cell Lung Cancer (PID1982)Tremelimumab 75 / Durvalumab 1500 / Gemcitabine 1250 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2293)Tremelimumab 75 / Durvalumab 1500 / Gemcitabine 1250 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2294)Tremelimumab 75 / Durvalumab 1500 / Nab-Paclitaxel 100 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2290)Tremelimumab 75 / Durvalumab 1500 / Pemetrexed 500 / Carboplatin 6, Non-Small Cell Lung Cancer, Cycle 1-4 (PID2295)Tremelimumab 75 / Durvalumab 1500 / Pemetrexed 500 / Cisplatin 75, Non-Small Cell Lung Cancer, Cycles 1-4 (PID2296)Tremelimumab 75 / Durvalumab 1500 / Pemetrexed 500, Non-Small Cell Lung Cancer, Cycle 6 (PID2298)Tremelimumab 75 / Durvalumab 1500, Non-Small Cell Lung Cancer, Cycle 6 (PID2292)Vemurafenib 960, Non-Small Cell Lung Cancer (PID1494)Vinorelbine 12.5 / Carboplatin 1 / Radiation, Non-Small Cell Lung Cancer (PID668)Vinorelbine 15 / Cisplatin 40 / Radiation, Non-Small Cell Lung Cancer, Part C (PID1169)Vinorelbine 15 / Cisplatin 80 / Radiation, Non-Small Cell Lung Cancer, B (PID262)Vinorelbine 20 / Cisplatin 50 / Radiation, Non-Small Cell Lung Cancer, Neoadjuvant, Part B (PID853)Vinorelbine 20 / Cisplatin 40 / Radiation, Non-Small Cell Lung Cancer (PID1193)Vinorelbine 20 / Cisplatin 80 / Radiation, Non-Small Cell Lung Cancer (PID646)Vinorelbine 25 / Cisplatin 100, Non-Small Cell Lung Cancer (PID147)Vinorelbine 25 / Cisplatin 50, Non-Small Cell Lung Cancer, Adjuvant (PID199)Vinorelbine 25 / Cisplatin 80, Non-Small Cell Lung Cancer, A (PID261)Vinorelbine 25 / Cisplatin 80, Non-Small Cell Lung Carcinoma, Adjuvant (PID34)Vinorelbine 25 / Gemcitabine 1000, Non-Small Cell Lung Carcinoma (PID152)Vinorelbine 30 / Cisplatin 100, Non-Small Cell Lung Carcinoma (PID150)Vinorelbine 30 / Cisplatin 100, Non-Small Cell Lung Cancer, Adjuvant (PID93)Vinorelbine 30 / Cisplatin 80, Non-Small Cell Lung Carcinoma (PID153)Vinorelbine 30 / Gemcitabine 1200, Non-Small Cell Lung Carcinoma (PID164)Vinorelbine 30, Non-Small Cell Lung Cancer (first-line) (PID165)Vinorelbine 30, Non-Small Cell Lung Cancer (second-line) (PID163)
